You are here

Home » Content

COST ANALYSIS STUDY OF ORAL ANTIDIABETIC DRUGS AVAILABLE IN INDIAN MARKET

COST ANALYSIS STUDY OF ORAL ANTIDIABETIC DRUGS AVAILABLE IN INDIAN MARKET

Journal Name:

  • International Journal of Medical Research & Health Sciences

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Introduction: There exists a wide range of variation in the prices of drugs marketed in India and other countries of the world. Very few studies have been conducted to reveal such price variations in the open market. Aim & Objectives: To evaluate the cost of oral anti-diabetics of different generic classes and different brand names of one compound, To evaluate the difference in cost of different brands for the same active drug by calculating percentage variation of cost. Methods: Cost of a particular drug being manufactured by different companies, in the same strength, number and dosage form was compared. The difference in the maximum and minimum price of the same drug manufactured by different pharmaceutical companies and the percentage variation in price was calculated. Results: In Single drug therapy, among sulfonylurea group of drugs, Glimepiride (1 mg) shows maximum price variation of 655.38%, while Glipizide (10mg) shows variation of 38.88%. In Biguanides & Thizolidinediones groups of drugs, Metformin (500 mg) & Pioglitazone (15 mg) show maximum price variation of 308.33% & 542% respectively. In α-glucosidases inhibitor group of drugs, Miglitol shows maximum price variation of 135.50 %. In combination therapies, Glipizide & Metformin combination shows the maximum variation up to 399.04 %. Conclusion: The average percentage price variation of different brands of the same drug manufactured in India is very wide and the appraisal and management of marketing drugs should be directed toward maximizing the benefits of therapy and minimizing negative personal and economic consequences.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-cost-analysis-study-oral-antidiabetic-drugs-available-indian-market.pdf
  • 1
63-69
  • Turkish

REFERENCES

References: 

1. Kuruvilla A, George K, Rajaratnam A, John
KR. Prescription patterns and cost analysis of
drugs in a base hospital in south India. Natl
Med J India. 1994 Jul-Aug; 7 (4): 167-68
2. Ravi Shankar P, Subish P, Bhandari RB,
Mishra P, Saha AC. Ambiguous pricing of
topical dermatological products: A survey of
brands from two South Asian countries.
Journal of Pakistan Assoctn. of
Dermatologists 2006; 16: 134-40
3. World Health Organization. Introduction to
drug utilization research. Oslo: 2003
4. Mohan V, Sandeep S, DeepaR, Shah B,
Varghese . Epidemiology of type 2 diabetes:
Indian scenario. Indian J Med Res. 2007;125:
217-30
5. Sicree R, Shaw J, Zimmet P. Diabetes and
impaired glucose tolerance. In: Gan D, editor.
Diabetes Atlas. International Diabetes
Federation. 3rd ed. Belgium: International
Diabetes Federation; 2006: 15-103
6. Scheen J, Lefebvre P.J. Oral Antidiabetic
Agents: A Guide to Selection : Drugs.1998;
55 ( 2): 225-36
7. Monaghan MJ, Monaghan MS. Do market
components account for higher US
prescription prices? Ann Pharmacother. 1996;
30: 1489-94
8. Sarkar P K. A rational drug policy. Indian J
Med Ethics 2004; 12; 30-35
68
Nisharani et al., Int J Med Res Health Sci. 2013;2(1): 63-69
9. Roy V, Rewari S. Ambiguous drug pricing: a
physician’s dilemma. Indian J Pharmacol
1998; 30: 404-07.
10. Wertheimer AI, Grumer SK. Overview of
international pharmacy pricing. Pharmacoeco
1992; 2: 449-55.
11. Berki SE, Richards JW, Weeks HA. The
mysteries of prescription pricing in retail
pharmacies. Med Care 1977; 15: 241-50.
12. Rataboli P, A Dang. Antimicrobial price
variation: Conundrum of medical profession.
JPGM. 2007;53 (1): 72-74
13. Das SC, Mandal M, Mandal SC. A critical
study on availability and price variation
between differ rent brands: Impact on access
to medicines. Indian Journal of
pharmaceutical sciences; 2007; 69 (1): 160-63
14. Sushma Dawadi, Rao BS, Khan GM. Pattern
of Antimicrobial Prescription and its Cost
Analysis in respiratory tract infection.
Kathmandu University Journal of Science,
Engineering and Technology. 2005:;1(1):1-9
15. Frazier LM, Brown JJ, Divine GW. Can
physician education lower the cost of
prescription drugs? A prospective Controlled
trial. Ann Intern Med. 1991; 115: 116-21.
16. Misra B, Jain SK, Mehta Y. A study on
availability and prices of medicines in India.
National Pharmaceutical Pricing Authority,
2002. Available from:
http://nppaindia.nic.in/index1.html.

Thank you for copying data from http://www.arastirmax.com